ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 145 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,529,905 | -41.6% | 661,300 | -11.6% | 0.00% | -100.0% |
| Q2 2023 | $7,757,434 | -36.3% | 748,065 | -50.3% | 0.00% | 0.0% |
| Q1 2023 | $12,184,204 | +0.1% | 1,506,082 | +95.0% | 0.00% | 0.0% |
| Q4 2022 | $12,166,497 | -32.5% | 772,476 | -32.6% | 0.00% | -50.0% |
| Q3 2022 | $18,028,000 | +3.9% | 1,145,339 | -7.8% | 0.00% | 0.0% |
| Q2 2022 | $17,343,000 | -17.1% | 1,242,308 | +2.4% | 0.00% | 0.0% |
| Q1 2022 | $20,918,000 | -2.8% | 1,213,350 | -18.0% | 0.00% | 0.0% |
| Q4 2021 | $21,519,000 | -24.5% | 1,479,989 | -6.5% | 0.00% | 0.0% |
| Q3 2021 | $28,496,000 | -4.1% | 1,583,089 | -6.4% | 0.00% | 0.0% |
| Q2 2021 | $29,711,000 | -21.5% | 1,691,974 | +12.7% | 0.00% | -33.3% |
| Q1 2021 | $37,825,000 | +2737.6% | 1,500,974 | +628.7% | 0.00% | – |
| Q4 2020 | $1,333,000 | +152.0% | 205,984 | 0.0% | 0.00% | – |
| Q3 2020 | $529,000 | +58.4% | 205,984 | 0.0% | 0.00% | – |
| Q2 2020 | $334,000 | +55.3% | 205,984 | -0.4% | 0.00% | – |
| Q1 2020 | $215,000 | -44.7% | 206,784 | +0.4% | 0.00% | – |
| Q4 2019 | $389,000 | +74.4% | 205,984 | -0.4% | 0.00% | – |
| Q3 2019 | $223,000 | -92.6% | 206,854 | -84.9% | 0.00% | – |
| Q2 2019 | $3,005,000 | -53.1% | 1,371,910 | +28.3% | 0.00% | -100.0% |
| Q1 2019 | $6,407,000 | -58.0% | 1,069,642 | -48.2% | 0.00% | -50.0% |
| Q4 2018 | $15,258,000 | -63.7% | 2,064,609 | -28.7% | 0.00% | -60.0% |
| Q3 2018 | $42,048,000 | -37.3% | 2,895,917 | -13.7% | 0.01% | -37.5% |
| Q2 2018 | $67,015,000 | +49.5% | 3,355,785 | +31.1% | 0.01% | +60.0% |
| Q1 2018 | $44,834,000 | -31.9% | 2,558,980 | -4.1% | 0.01% | -37.5% |
| Q4 2017 | $65,834,000 | +18.4% | 2,669,659 | +23.9% | 0.01% | +14.3% |
| Q3 2017 | $55,621,000 | +8.2% | 2,155,020 | +13.6% | 0.01% | +16.7% |
| Q2 2017 | $51,425,000 | +4.3% | 1,896,206 | +14.6% | 0.01% | 0.0% |
| Q1 2017 | $49,321,000 | +288.0% | 1,653,937 | +253.1% | 0.01% | +200.0% |
| Q4 2016 | $12,711,000 | -81.3% | 468,339 | -82.4% | 0.00% | -77.8% |
| Q3 2016 | $68,105,000 | +32.2% | 2,659,327 | -4.7% | 0.01% | +28.6% |
| Q2 2016 | $51,529,000 | -28.5% | 2,789,898 | -26.7% | 0.01% | -30.0% |
| Q1 2016 | $72,091,000 | -29.7% | 3,804,279 | 0.0% | 0.01% | -28.6% |
| Q4 2015 | $102,487,000 | – | 3,804,279 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |